Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults

n engl j med 373;16 nejm.org october 15, 2015 1575 Observations from each trajectory are also interesting (Table 1). An FEV1 that is normal at cohort inception without COPD at the final examination (trajectory 1) seems reasonable. An FEV1 that is normal or low at cohort inception with concomitant COPD at the final examination (trajectories 3 and 4) does also, especially considering the authors’ careful description of the participants assigned to trajectory 4. The longterm, 20% increase in FEV1 reported for participants in trajectory 2, though, is noteworthy.2 The stable ratio of FEV1 to forced vital capacity (FVC) in participants in trajectory 2 (79±12 vs. 76±5) would imply a similar increase in FVC. Can the authors provide a second conclusion from their study?